Skip to main content
. 2022 Feb 24;10:148–161. doi: 10.1016/j.xjon.2022.02.019

Table 4.

Comparison of adjusted outcomes of treatment groups with Concomitant as reference

Adjusted odds ratio or β-coefficient (95% CI) P value
Mortality
 Early-Staged 0.93 (0.20-4.25) .93
 Late-Staged 1.48 (0.45-4.86) .52
Stroke
 Early-Staged 1.38 (0.48-4.01) .55
 Late-Staged 1.65 (0.76-3.57) .21
Post-procedural hemorrhage
 Early-Staged 1.86 (0.43-8.09) .41
 Late-Staged 1.45 (0.41-5.08) .56
Blood transfusion
 Early-Staged 0.92 (0.53-1.57) .75
 Late-Staged 1.18 (0.78-1.79) .43
Acute kidney injury
 Early-Staged 2.68 (1.57-4.55) <.001
 Late-Staged 1.97 (1.29-2.99) .002
Pacemaker implantation
 Early-Staged 1.47 (0.94-2.28) .088
 Late-Staged 0.98 (0.68-1.41) .91
Non-home discharge
 Early-Staged 5.60 (3.65-8.59) <.001
 Late-Staged 2.87 (2.14-3.86) <.001
Post-TAVR length of stay, days
 Early-Staged 0.5 (−0.2 to 1.2) .14
 Late-Staged 0.3 (−0.1 to 0.7) .21
Total length of stay, days
 Early-Staged 3.0 (2.0-4.1) <.001
 Late-Staged 4.7 (4.0-5.3) <.001
Total hospitalization costs per $1000
 Early-Staged 6.6 (1.4-11.9) .014
 Late-Staged 13.3 (9.2-17.4) <.001
30-Day readmission
 Early-Staged 1.35 (0.86-2.12) .19
 Late-Staged 1.27 (0.86-1.87) .24

Binary outcomes are reported as adjusted odds ratio whereas continuous outcomes are reported as β-coefficient. CI, Confidence interval; TAVR, transcatheter aortic valve replacement.